Mima Akira, Gotoda Hidemasa, Lee Shinji
Nephrology, Osaka Medical and Pharmaceutical University, Takatsuki, JPN.
Cureus. 2024 Mar 31;16(3):e57362. doi: 10.7759/cureus.57362. eCollection 2024 Mar.
Introduction Dotinurad is being developed as a selective uric acid reabsorption inhibitor. However, its effect on lowering serum uric acid (UA) levels in chronic kidney disease (CKD) patients with severe renal dysfunction is unknown. Therefore, the purpose of this study was to determine the effect of dotinurad on renal function in CKD patients with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m. Methods Seven patients with CKD who received dotinurad 0.5 mg to 4 mg per day were studied retrospectively. Changes in UA, eGFR, and urine protein-to-creatinine ratio (UPCR) were analyzed. The observation period was 10.9±2.1 months. Results Serum UA levels were decreased and maintained with dotinurad administration. Nevertheless, there were no improvements noted in renal function. Additionally, no serious adverse effects were identified in any of the patients throughout the observation period. Conclusion Although the sample size in this study was small, our findings demonstrate the efficacy of dotinurad in individuals with advanced CKD who have an eGFR lower than 25 mL/min/1.73 m.
度洛尿酸正在作为一种选择性尿酸重吸收抑制剂进行研发。然而，其对严重肾功能不全的慢性肾脏病（CKD）患者降低血清尿酸（UA）水平的作用尚不清楚。因此，本研究的目的是确定度洛尿酸对估算肾小球滤过率（eGFR）低于25 mL/min/1.73 m²的CKD患者肾功能的影响。方法：回顾性研究7例每天接受0.5 mg至4 mg度洛尿酸治疗的CKD患者。分析UA、eGFR和尿蛋白肌酐比值（UPCR）的变化。观察期为10.9±2.1个月。结果：给予度洛尿酸后血清UA水平降低并维持。然而，肾功能未见改善。此外，在整个观察期内，未在任何患者中发现严重不良反应。结论：尽管本研究的样本量较小，但我们的研究结果表明度洛尿酸对eGFR低于25 mL/min/1.73 m²的晚期CKD患者有效。
